Accessibility Menu
BioNexus Gene Lab logo

BioNexus Gene Lab(NASDAQ) BGLC

Market Cap$3.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-97%
5 Year-91%
1 Year-72%
1 Month-17%
$1.58
+2.60%
+0.04Today
After hours$1.57-$0.01 (-0.63%)
BioNexus Gene Lab last closing stock price
MetricPriceDate
Last closeUSD 1.582026-08-06
BioNexus Gene Lab stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+19.7%USD 1.322026-07-30
1 month-17.28%USD 1.912026-07-07
3 month-23.3%USD 2.062026-05-08
Year to date-60%USD 3.952025-12-31
1 year-72.08%USD 5.662025-08-06
3 year-90.25%USD 16.202023-08-07
5 year-90.65%USD 16.902021-08-06
Since inception-96.79%USD 49.202020-09-16

BioNexus Gene Lab Financials at a Glance

Market Cap

$3.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.31M

Net Income (TTM)

-$2.90M

EPS (TTM)

-$1.49

P/E Ratio

-1.06

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$1.58

Volume

5,918

Open

$1.55

Previous Close

$1.58

Daily Range

$1.55 - $1.58

52-Week Range

$1.07 - $6.10

Estimated Earnings Date

Apr 14, 2026

BGLC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioNexus Gene Lab

BioNexus Gene Lab helps factories get key chemicals and doctors detect disease risks early. Its chemicals build things like handrails and car parts. Its blood tests help spot cancer and other health risks before symptoms appear.

Products and Services

  • Industrial Chemicals (Chemrex, 99.7% of FY2025 revenue): Supplies fiber-reinforced polymers for manufacturers making handrails, bench tops, and auto parts.
  • Genomic Diagnostics (MRNA Scientific, 0.3% of FY2025 revenue): Offers blood-based tests to detect early signs of cancer and chronic diseases.
  • AI-Enabled Liquid Biopsy: Provides cancer recurrence monitoring using the VitaGuard platform, licensed for Southeast Asia.
  • Digital Asset Treasury: Manages part of its cash in Ethereum, a digital currency, for diversification.

Growth and Expansion

  • 2023: Listed on NASDAQ Capital Market.
  • 2024: Expanded manufacturing with new color paste facility.
  • 2025: Secured exclusive Southeast Asia license for VitaGuard liquid biopsy from Fidelion Diagnostics.
  • 2025: Launched Ethereum-focused treasury strategy with ML Tech.
  • 2025: Entered $100M shelf registration and $20M equity program with Maxim Group.

What Makes BioNexus Gene Lab Stand Out

The company serves both industrial and healthcare markets across Southeast Asia. It combines established chemical supply chains with proprietary medical diagnostics. Exclusive regional rights to new cancer monitoring technology add a unique healthcare angle.

Five Things You Need to Know

  • FY2025 revenue was $7.4 million, down 21.9% from FY2024.
  • Chemrex chemicals made up 99.7% of FY2025 revenue.
  • MRNA Scientific diagnostics grew 18.8% YoY but remain a small segment.
  • Operating loss rose to $3.0 million in FY2025, up 88% from FY2024.
  • Auditor notes substantial doubt about the company’s ability to continue as a going concern.

Bottom Line

BioNexus Gene Lab has diversified from chemicals into medical diagnostics. The company faces financial challenges but continues to pursue new technologies and markets.

AI Generated • Apr 16, 2026

Industry

Trading Companies and Distributors

Sector

Industrials

Employees

16

CEO

Su Leng Tan Lee

Website

www.bionexusgenelab.com

Headquarters

Kuala Lumpur, WP 59200, MY

BGLC Financials

Key Financial Metrics (TTM)

Gross Margin

13.54%

Operating Margin

-54.93%

Net Income Margin

-54.70%

Return on Equity

-37.43%

Return on Capital

-35.93%

Return on Assets

-13.70%

Earnings Yield

-94.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.42M

Volume

5.92K

Avg. Volume

101.41K

Financials (TTM)

Gross Profit

$718.99K

Operating Income

-$2.92M

EBITDA

-$2.72M

Operating Cash Flow

-$1.16M

Capital Expenditure

-$28.25K

Free Cash Flow

-$1.19M

Cash & ST Invst.

$3.96M

Total Debt

$216.43K

BioNexus Gene Lab Performance Analysis

BioNexus Gene Lab annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 10,928,707-18.2%
20232023-12-31USD 9,770,806-10.6%
20242024-12-31USD 9,510,646-2.7%
20252025-12-31USD 7,424,911-21.9%
BioNexus Gene Lab sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.8%
Q32025-09-3012.5%
Q42025-12-31-81.0%
Q12026-03-31-95.3%
BioNexus Gene Lab annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.25N/A
20232023-12-31USD -1.66569.9%
20242024-12-31USD -0.90-45.8%
20252025-12-31USD -1.6179.2%
BioNexus Gene Lab sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-302.9%
Q32025-09-30-14.7%
Q42025-12-31-35.9%
Q12026-03-3158.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$22.84K

-98.9%

Gross Profit

-$22.73K

-106.6%

Gross Margin

-99.51%

N/A

Market Cap

$3.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$201.02K

N/A

Employees

19

N/A

Net Income

-$543.58K

+12.8%

EBITDA

-$496.61K

+9.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.96M

+10.3%

Total Debt

$216.43K

+8.2%

Accounts Receivable

$141.47K

-90.8%

Inventory

$667.15K

-43.4%

Long Term Debt

$150.41K

+1.7%

Short Term Debt

$66.02K

+26.5%

Return on Assets

-13.70%

N/A

Return on Invested Capital

-14.30%

N/A

Free Cash Flow

-$148.00K

+82.2%

Operating Cash Flow

-$147.67K

+82.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XAIRBeyond Air, Inc.
$5.56-2.28%
MBIOMustang Bio, Inc.
$0.58-3.64%
APMAptorum Group Limited
$8.26-14.84%
LYRALyra Therapeutics, Inc.
$0.40-15.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%
SPCXSpace Exploration Technologies
$114.92+0.06%

Questions About BGLC

What is the current price of BioNexus Gene Lab?

BioNexus Gene Lab is trading at $1.58 per share.

What is the 52-week range for BioNexus Gene Lab?

Over the past 52 weeks, BioNexus Gene Lab has traded between $1.07 and $6.10.

How much debt does BioNexus Gene Lab have?

As of the most recent reporting period, BioNexus Gene Lab reported total debt of $216.43K.

How much cash does BioNexus Gene Lab have on hand?

BioNexus Gene Lab reported $3.96M in cash and cash equivalents in its most recent financial results.

What is BioNexus Gene Lab’s dividend yield?

BioNexus Gene Lab does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services